Pharmafile Logo
Pharmafocus logo
Advanced Search

Opthalmology

Showing 15 posts of 30 posts found.

Provectus Biopharmaceuticals announces license agreement with University of Miami

March 28, 2024
Business Services License Agreement, Opthalmology, Provectus Biopharmaceuticals, University of Miami

Provectus Biopharmaceuticals has announced that it has entered into an exclusive worldwide license agreement with the University of Miami, US …

News

FDA approves Glaukos’ iDose TR treatment for glaucoma disease

December 15, 2023
Medical Communications FDA, Glaukos, Opthalmology, iDose TR, ocular hypertension, open-angle glaucoma

Glaukos Corporation has announced that the US Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for …

News

Aldeyra Therapeutics and AbbVie enter agreement for development and commercialisation of reproxalap

November 2, 2023
Business Services AbbVie, Aldeyra Therapeutics, Opthalmology, reproxalap

Aldeyra Therapeutics and AbbVie have announced that they have entered into an exclusive option agreement for the license to develop, …

News

Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment

October 27, 2023
Medical Communications FDA, Opthalmology, Roche, Vabysmo, retinal vein occlusion

Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) for the treatment of macular …

News

Genentech shares data from phase 3 trials of Vabysmo for retinal vein occlusion treatment

October 10, 2023
Research and Development Genentech, Opthalmology, Vabysmo, phase 3 trial, retinal vein occlusion

Genentech has announced positive topline long-term results from its global phase 3 BALATON and COMINO trials which assessed extended treatment …

News

Tarsus Pharmaceuticals’ Xdemvy approved by FDA for treatment of Demodex blepharitis

August 25, 2023
Medical Communications Demodex blepharitis, FDA, Opthalmology, Tarsus Pharmaceuticals, eyedrops

Tarsus Pharmaceuticals has announced that the US Food and Drug Administration (FDA) approved its drug Xdemvy (lotillaner ophthalmic solution) 0.25% …

News

Iveric Bio’s marketing authorisation application for avacincaptad pegol accepted by EMA

August 18, 2023
Medical Communications CHMP, EMA, Iveric Bio, MAA, Opthalmology

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for avacincaptad pegol …

News
eye1

Sandoz shares positive results from MYLIGHT phase 3 study

August 16, 2023
Research and Development Opthalmology, Sandoz, aflibercept, clinical trial, wet macular degeneration

Sandoz has announced positive results from the phase 3 MYLIGHT confirmatory efficacy and safety study for its biosimilar aflibercept, for …

News
eye_2

Regeneron shares two-year PULSAR trial results for wAMD

August 11, 2023
Medical Communications Opthalmology, PULSAR trial, Regeneron, wAMD

Regeneron Pharmaceuticals have announced positive, two-year, topline results from its PULSAR trial assessing aflibercept 8mg for the treatment of patients …

News

Oculis announces positive results from phase 3 OPTIMIZE trial

August 9, 2023
Research and Development Oculis, Opthalmology, clinical trial, eyedrops, ocular surgery

Oculis has announced positive topline results from its phase 3 OPTIMIZE trial for its OCS-01 eyedrops, a once daily, high …

News
eye2

Astellas announces FDA approval for Izervay for GA treatment

August 7, 2023
Medical Communications AMD, Astellas Pharma, FDA, Izervay, Opthalmology, geographic atrophy

Astellas Pharma has announced that the US Food and Drug Administration (FDA) has approved Izervay (avacincaptag pegol intravitreal solution) for …

News
eye2

Astellas and 4D Molecular Therapeutics enter license agreement for rare ophthalmic targets

July 11, 2023
Research and Development 4D Molecular Therapeutics, AAV vectors, Astellas Pharma, Opthalmology, ophthalmology

Astellas Pharma and 4D Molecular Therapeutics (4DMT) have announced a license agreement under which Astellas has the right to use …

News

Skyline Therapeutics receives FDA clearance of IND for candidate for neovascular age-related macular degeneration

July 5, 2023
Research and Development FDA, IND, Opthalmology, Skyline Therapeutics, neovascular age-related macular degeneration

Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …

News

More infections from contaminated eyedrops increase death toll

May 23, 2023
Medical Communications FDA, Opthalmology, eyedrops, infections

The US Centers for Disease Control and Prevention (CDC) have released updated data regarding contaminated eyedrops. As of May 2023, …

News

Eyenovia announces FDA approval of first ophthalmic spray for mydriasis

May 10, 2023
Research and Development Eyenovia, FDA, Opthalmology, mydriasis, ophthalmology

Ophthalmic technology company Eyenovia has announced that the US Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025